Generic Drug Sponsors Seek Advance Notice Of Approvals From US FDA
Executive Summary
Pre-launch communication from agency would allow sponsors to ramp up commercial activities and could head off some innovator company legal challenges to ANDA approvals, attorneys say; CDER’s Moscicki suggests GDUFA goal dates now provide sponsors some level of predictability.
You may also be interested in...
US FDA To Generic Sponsors: Don't Call Us, We'll GDUFA You
FDA says there are only a few situations where the ANDA status call to the project manager is necessary, and industry seems to agree that review system improvements make the once-contentious check-in process less necessary.
US FDA To Generic Sponsors: Don't Call Us, We'll GDUFA You
FDA says there are only a few situations where the ANDA status call to the project manager is necessary, and industry seems to agree that review system improvements make the once-contentious check-in process less necessary.
Generic User Fee Transition A Little Bumpy For Contract Manufacturers
Problems with self-identification process caused by timing of legislative renewal may have affected figures used by US FDA to calculate FY 2018 GDUFA fees.